{"nctId":"NCT00607243","briefTitle":"Safety and Efficacy of CJ-50300 in Healthy Volunteers","startDateStruct":{"date":"2008-01"},"conditions":["Smallpox"],"count":123,"armGroups":[{"label":"Conventional dose group","type":"EXPERIMENTAL","interventionNames":["Biological: smallpox vaccine CJ-50300"]},{"label":"Low dose group","type":"EXPERIMENTAL","interventionNames":["Biological: smallpox vaccine CJ-50300"]}],"interventions":[{"name":"smallpox vaccine CJ-50300","otherNames":["CJ-53300"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy Korean male and female subjects between 20 and 60 years of age at the time of screening visit\n2. Willing to participate and have signed the informed consent form\n3. In good general health, without clinically skin diseases history, physical examination or laboratory test results\n4. Hematocrit \\> 33% for women; \\> 38% for men\n5. White cell count 3,300-12,000/mm3\n6. Total lymphocyte count \\> 800 cells/mm3\n7. Subjects who have never been vaccinated with smallpox vaccines\n\nExclusion Criteria:\n\n1. Diseases or conditions that cause immunodeficiency (For examples; HIV AIDS, leukemia, lymphoma, generalized malignancy, agammaglobulinemia, history of transplantation, therapy with alkylating agents, antimetabolites, radiation, or oral or parenteral corticosteroids).\n2. In close physical contact (household or at work) with an individual who has the diseases or conditions that cause immunodeficiency\n3. History or present of eczema or atopic dermatitis\n4. Allergy or sensitivity to any known components of vaccine or other medicines\n5. In close physical contact (household or at work) with an individual who has acute or chronic skin conditions such as dermatitis, exfoliative dermatitis\n6. Subjects requiring steroid therapy\n7. Subjects who are taking immunosuppressive therapy\n8. Subjects who are planning for blood donations\n9. Autoimmune disease such as lupus erythematosus\n10. Subjects who work in medical institution\n11. Household contacts with women who are pregnant or breast-feeding\n12. Female subjects who are pregnant or breast-feeding and have positive result by serum pregnancy test or urine pregnancy test, or do not using approved contraceptives such as sterilization, contraceptive ring injectable, combined oral contraceptive pills and barrier contraceptive, combined hormone-based therapy, contraceptive cream, contraceptive jelly, diaphragm or condoms\n13. Subjects household member \\< 1 year old or work with children \\< 1 year old\n14. Subjects with a known history of Cardiac disease or have three or more of the following risk factors: hyperpiesia, obesity, hyperlipidemia, glucosuria, sclerosis, cerebral arteriosclerosis\n15. Receipt of immunoglobulin and steroid within 14 days of vaccination\n16. Receipt of investigational research agents within 120 days of vaccination\n17. HBsAg seropositive\n18. HCV antibody seropositive\n19. HIV seropositive\n20. Subjects having fever (oral temperature \\> 38â„ƒ) or severe nutrition disorder\n21. Blood donation within 12 weeks in advance screening visit\n22. Subject who are not suitable to participate in study according to investigator's judgement","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cutaneous Take Reaction","description":"The \"take reaction\"was defined as a vesicular or pustular lesion or an area of definite palpable induration or congestion surrounding a central lesion (a crust or ulcer) occurring at the vaccination site at any of post-vaccination days (PVDs) 6-8. The vaccination site was photographed, and measures were taken.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Reactions","description":null,"classes":[]},{"type":"SECONDARY","title":"Antibody Response","description":null,"classes":[]},{"type":"SECONDARY","title":"Cell-mediate Immunity","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":82},"commonTop":["Axillary pain or lymphadenopathy","Pain at vaccination site","Fatigue","Headache","Myalgia"]}}}